Companies Dominating the Radiotheranostics Landscape
- TransCode Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Clarity Pharmaceuticals
- Ariceum Therapeutics GmbH
- Novartis AG
- Bayer AG
- Progenics Pharmaceuticals, Inc.
- Telix Pharmacuticals Limited
- ITM Radiopharma
- Life Molecular Imaging
- RadioMedix
- Hitachi, Ltd.
- Chiba University
- Shimadzu Corporation
- Canon Medical System Corporation
- Toshiba Corporation
Browse Key Market Insights with Data Illustration:
In the News
- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.
- Clarity Pharmaceuticals announced that the first patient in its phase1/2theranostic trial, which is testing 64Cu/67Cu SAR-bisPSMA theranostic product in people with metastatic castrate-restant prostate cancer, has been given a dose. The promising preclinical and clinical result so far support clarity’s investigation of the optimised SAR-bisPSMA product in additional oncology indications where the theranostic approach may be useful.
